MedElevator Войти в исследования
← Поиск публикаций

DOI 10.2967/jnumed.125.269863

Медицинская библиотека · Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025

Diagnostic Performance of the 68Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine Tumors.

Uprimny Christian, von Guggenberg Elisabeth, Sviridenko Anna, Bayerschmidt Steffen, Rossetti Lisa Maria, Roustaei Hessamoddin, Warwitz Boris, Ulmer Hanno, Hutter Angelika, di Santo Gianpaolo, Virgolini Irene J

СтатьяКлиническое исследование II фазыКлиническое исследование I фазыПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

A prospective phase 1/2a pilot study (NCT06155994) was performed at our center to compare the diagnostic performance of cholecystokinin-2 receptor (CCK2R) PET/CT imaging with the 68Ga-labeled peptide analog DOTA-DGlu-Ala-Tyr-Gly-Trp-(N-Me)Nle-Asp-1-Nal-Phe-NH2 (68Ga-DOTA-MGS5) with that of the reference standard PET/CT.

Methods

Six patients with advanced medullary thyroid cancer (MTC) and 6 patients with other neuroendocrine tumors (NETs)-4 with gastroenteropancreatic (GEP) NETs and 2 with bronchopulmonary (BP) NETs-were included in the study. All patients had known metastases, documented by 68Ga-DOTATOC and 18F-DOPA PET/CT. Intensity of tracer accumulation (SUVmax/SUVmean) of normal tissue and lesions judged malignant was compared with standard PET imaging (number of lesions, uptake per lesion).

Results

When compared with standard imaging, 68Ga-DOTA-MGS5 showed significantly increased blood-pool activity (P ≤ 0.009), with improved lesion contrast at 2 h after injection compared with 1 h after injection. Four of 6 patients with MTC had positive lesions on 68Ga-DOTA-MGS5 PET/CT. Fifty-one lesions were detected with 18F-DOPA versus 48 with 68Ga-DOTA-MGS5, with a significantly higher mean SUVmax of 7.2 at 1 h and 2 h after injection versus 4.7 with 18F-DOPA (P < 0.001). In the 2 patients with MTC imaged with 68Ga-DOTATOC and 68Ga-DOTA-MGS5, the same total number of lesions (n = 14) was detected (mean SUVmax, 24.3 vs. 17.4 and 18.7 at 1 and 2 h after injection, respectively; P > 0.5). In patients with non-MTC NETs, 26 CCK2R-positive lesions were confirmed for 2 patients with BP-NETs compared with 45 lesions visualized with 68Ga-DOTATOC. In the 4 patients with GEP-NETs, only 1 of 21 lesions displaying positive uptake on 68Ga-DOTATOC PET/CT was visualized with 68Ga-DOTA-MGS5 (an ileal NET), whereas the lesions in the other 3 patients were negative on 68Ga-DOTA-MGS5 PET/CT.

Conclusion

CCK2R PET/CT using 68Ga-DOTA-MGS5 showed a high tumor lesion detection rate in patients with MTC, with lesion uptake values comparable to those with 18F-DOPA and 68Ga-DOTATOC. In patients with non-MTC NETs, 68Ga-DOTA-MGS5 PET/CT showed possible applicability in patients with BP-NETs, which needs to be verified in a larger patient cohort. In contrast, 68Ga-DOTA-MGS5 PET/CT seemed to be of limited value in patients with GEP-NETs.

Для цитирования: Uprimny Christian, von Guggenberg Elisabeth, Sviridenko Anna, Bayerschmidt Steffen, Rossetti Lisa Maria, Roustaei Hessamoddin, Warwitz Boris, Ulmer Hanno, Hutter Angelika, di Santo Gianpaolo, Virgolini Irene J. Diagnostic Performance of the 68Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine Tumors.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2025. DOI: 10.2967/jnumed.125.269863.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.